<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65689">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02250703</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0131</org_study_id>
    <nct_id>NCT02250703</nct_id>
  </id_info>
  <brief_title>Intranasal Dexmedetomidine Premedication in Children</brief_title>
  <official_title>Comparing Intranasal Dexmedetomidine With Oral Midazolam as Premedication for Older Children Undergoing General Anesthesia for Dental Rehabilitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND INFORMATION AND RATIONALE

      Pediatric patients scheduled for dental procedures under general anesthesia can have
      significant anxiety before the procedure. They are commonly pre medicated to minimize
      distress and to facilitate a smooth induction of anesthesia. Oral Midazolam at 0.5mg/kg dose
      is more widely used for this purpose . However the commonly used maximum dose is up to 15mg.
      It also has many limitations such as paradoxical reaction, increased incidence of emergence
      delirium and negative postoperative behavior changes . Intranasal dexmedetomidine has been
      used an effective and safe alternative premedication to oral midazolam in children. At a
      dose of 2micrograms/kg, intranasal dexmedetomidine as premedication resulted in excellent
      sedation in children aged 5-8yrs with no adverse hemodynamic effects. It has other
      advantages such as providing analgesia and facilitating smooth emergence from anesthesia.

      The goal of this study is to find out if intranasal dexmedetomidine is a superior
      alternative as premedication to oral midazolam in children weighing more than 20kg
      undergoing general anesthesia for dental rehabilitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After IRB approval and written informed consent from patients' parents or legally authorized
      representative, 80 children older than 5yrs and weighing more than 20kg, ASA physical status
      1 or 2, scheduled for elective dental rehabilitation with general anesthesia will be
      enrolled in this prospective randomized double blinded study.

      Exclusion criteria include known allergy or hypersensitivity to midazolam or
      dexmedetomidine, uncorrected congenital heart disease or history of cardiac arrhythmia,
      children at risk for airway obstruction (OSA or cranio facial syndrome) and pregnant minors
      Patients will be randomly assigned to one of two groups M (midazolam) or D (dexmedetomidine)
      using computer-generated numbers in sealed envelopes.

      All the patients will be brought to their pre-op room and premedicated at least 30 min
      before induction of anesthesia.

      In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml
      parenteral preparation) mixed with flavored syrup.

      In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of
      100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be
      administered using a intranasal mucosal administration device (LMA MAD NasalTM). Atomized
      nasal medications offer rapid absorption across mucosal membranes to the blood stream
      avoiding first-pass metabolism.

      Parents will be present in the room during premedication. The Anesthesia personnel involved
      in the care of the patient (MD or CRNA) will prepare and administer all study drugs. All
      patients will be continuously monitored in the holding area with pulse oximetry and blood
      pressure monitor. HR, SPO2 and BP will be recorded every 15min after administration of
      premedication until transfer to the OR. Emergency medications including atropine and
      epinephrine will be immediately available in the pre-op holding area. Oral midazolam has
      been used with very little effect on hemodynamic parameters. Although intranasal
      dexmedetomidine can decrease HR and BP, it has been used at the dose of 2mcg/kg without any
      adverse hemodynamic effect . Any intervention needed to treat drop in HR (&lt;50) and BP (sys
      BP &lt;60) after the drug administration will be recorded.

      Behavior of the children at the time of premedication will be documented ( easy or
      difficult). Any unwanted effects during administration such as spitting or vomiting of oral
      drug and pain or irritation from nasal administration will be documented.

      The dental resident blinded to study drug administration will do the pre-operative sedation
      status and acceptance of mask induction.

      Sedation status will be assessed using University of Michigan sedation scale (UMSS)on
      separation from parents and at induction after moving to the OR table. Acceptance of mask
      induction will be documented on a 4-point scale.

      Standard ASA monitors will be applied before induction of anesthesia. All patients will
      undergo mask induction with O2/N2O/Sevo. An intravenous line will be inserted and secured.
      Both nostrils will be prepped nasal drops and tips of tracheal tubes covered with red rubber
      to minimize bleeding. Nasal intubation will be performed with direct laryngoscopy and
      McGill's forceps. Appropriate size cuffed tracheal tubes will be inserted and secured after
      additional IV medications with propofol 2-3mg/kg and fentanyl 1-2mcg/kg. Anesthesia will be
      maintained with O2/Sevo, IV morphine 0.05 to 0.1mg/kg and IV toradol 0.5mg/kg (if there is
      no allergy or contraindication to morphine or toradol) After the completion of procedure,
      patients will be extubated in the operating room and brought to recovery room and allowed to
      wake up slowly in the recovery position.

      PACU nurses will evaluate Behavior at awakening using four-point wake up score (9,20).
      Patients will also be asked if they remember mask induction (yes or no) when they are ready
      for discharge. Incidence of nausea, vomiting, shivering will be documented in PACU. Time
      spent in phase 1 recovery room will also be recorded .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>University of Michigan Sedation Scale</measure>
    <time_frame>Day 0:Just before the patient will be brought to the operating room</time_frame>
    <description>Level of sedation at separation from parents and at the time of mask induction will be measured on a scale of 0 to 4 (University of Michigan Sedation Scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptance of mask induction</measure>
    <time_frame>Day 0: At the time when anesthesia is induced</time_frame>
    <description>on a scale of 1 to 4
excellent( cooperative)
good( slight fear, easily calmed)
fair ( moderate fear, not calmed with reassurance)
Poor( agitated, terrified)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wake up behavior</measure>
    <time_frame>Day 0: At the end of surgery when the patient recovers from anesthesia</time_frame>
    <description>assessed in post anesthesia recovery unit after the procedure on a scale of 1o 4
calm
not calm but easily calmed
moderately agitated or restless
combative/disoriented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of amnesia to mask induction</measure>
    <time_frame>Day 0: at the time of discharge of the patient from the recovery room</time_frame>
    <description>Yes or No (if the patient remembers mask induction)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Preoperative Sedation</condition>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral midazolam syrup</intervention_name>
    <description>oral midazolam 0.5mg/kg upto maximum dose of 15mg</description>
    <arm_group_label>Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal dexmedetomidine</intervention_name>
    <description>intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dental surgery</intervention_name>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N2O and Sevoflurane</intervention_name>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>General Anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl and Propofol</intervention_name>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Intravenous induction agents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine and Toradol</intervention_name>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Intravenous Pain medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children older than 5yrs and weighing more than 20kg , who are scheduled for
             ambulatory dental rehabilitation at Batson operating rooms.

          -  ASA classification 1 or 2

        Exclusion Criteria

          -  Known allergy to midazolam, dexmedetomidine,morphine, fentanyl, sevoflurane and
             propofol.

          -  uncorrected congenital heart disease or history of cardiac arrhythmia,

          -  children at risk for airway obstruction (OSA or cranio facial syndrome),

          -  pregnant minors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Madhankumar Sathyamoorthy, MBBS, MS</last_name>
    <phone>6035664660</phone>
    <email>msathyamoorthy@umc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's of Mississippi/University of Mississipi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhankumar Sathyamoorthy, MBBS, MS</last_name>
      <phone>603-566-4660</phone>
      <email>msathyamoorthy@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Madhankumar Sathyamoorthy, MBBS, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kain ZN, Mayes LC, Bell C, Weisman S, Hofstadter MB, Rimar S. Premedication in the United States: a status report. Anesth Analg. 1997 Feb;84(2):427-32.</citation>
    <PMID>9024042</PMID>
  </reference>
  <reference>
    <citation>LÃ¶nnqvist PA, Habre W. Midazolam as premedication: is the emperor naked or just half-dressed? Paediatr Anaesth. 2005 Apr;15(4):263-5.</citation>
    <PMID>15787915</PMID>
  </reference>
  <reference>
    <citation>Kanegaye JT, Favela JL, Acosta M, Bank DE. High-dose rectal midazolam for pediatric procedures: a randomized trial of sedative efficacy and agitation. Pediatr Emerg Care. 2003 Oct;19(5):329-36.</citation>
    <PMID>14578832</PMID>
  </reference>
  <reference>
    <citation>McGraw T, Kendrick A. Oral midazolam premedication and postoperative behaviour in children. Paediatr Anaesth. 1998;8(2):117-21.</citation>
    <PMID>9549736</PMID>
  </reference>
  <results_reference>
    <citation>Kain ZN, Caldwell-Andrews AA, Krivutza DM, Weinberg ME, Wang SM, Gaal D. Trends in the practice of parental presence during induction of anesthesia and the use of preoperative sedative premedication in the United States, 1995-2002: results of a follow-up national survey. Anesth Analg. 2004 May;98(5):1252-9, table of contents.</citation>
    <PMID>15105196</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuen VM, Hui TW, Irwin MG, Yuen MK. A comparison of intranasal dexmedetomidine and oral midazolam for premedication in pediatric anesthesia: a double-blinded randomized controlled trial. Anesth Analg. 2008 Jun;106(6):1715-21. doi: 10.1213/ane.0b013e31816c8929.</citation>
    <PMID>18499600</PMID>
  </results_reference>
  <results_reference>
    <citation>Akin A, Bayram A, Esmaoglu A, Tosun Z, Aksu R, Altuntas R, Boyaci A. Dexmedetomidine vs midazolam for premedication of pediatric patients undergoing anesthesia. Paediatr Anaesth. 2012 Sep;22(9):871-6. doi: 10.1111/j.1460-9592.2012.03802.x. Epub 2012 Jan 23.</citation>
    <PMID>22268591</PMID>
  </results_reference>
  <results_reference>
    <citation>Sheta SA, Al-Sarheed MA, Abdelhalim AA. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: a double-blinded randomized controlled trial. Paediatr Anaesth. 2014 Feb;24(2):181-9. doi: 10.1111/pan.12287. Epub 2013 Nov 15.</citation>
    <PMID>24237879</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuen VM, Hui TW, Irwin MG, Yao TJ, Chan L, Wong GL, Shahnaz Hasan M, Shariffuddin II. A randomised comparison of two intranasal dexmedetomidine doses for premedication in children. Anaesthesia. 2012 Nov;67(11):1210-6. doi: 10.1111/j.1365-2044.2012.07309.x. Epub 2012 Sep 5.</citation>
    <PMID>22950484</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 16, 2015</lastchanged_date>
  <firstreceived_date>September 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Madhankumar Sathyamoorthy</investigator_full_name>
    <investigator_title>Assisitant Professor</investigator_title>
  </responsible_party>
  <keyword>Premedication</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Anesthetics, Intravenous</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
